Subject Index
Coagulation Factors and Inhibitors
Fibrinolysis, fibrinogen, fibrin
Haemorrhagic Disorders
Invited
Other
Platelets
Thrombotic Disorders and antithrombotic therapy
Vascular Biology
Coagulation Factors and Inhibitors
Animal and experimental models
AT, HCII, serine protease inhibitors
Contact phase
Factor IX and vitamin K-dependent factors
Factor XIII
Factor VIII, factor V
Methods
Other coagulation factors and inhibitions
Procoagulant phospholipids
Protein C, protein S, thrombomodulin
Structural biology and drug design
Thrombin, thrombin receptors
Tissue factor, TFPI, factor VII
Association of factor X with lipid rafts in the presence of active cofactor (factor VIIIa) promotes the assembly of factor-X activating complex on the activated platelet membrane
Ahmad S. S., Walsh P. N.
Calcium ion-independent structure of the factor IX w-loop peptide, FIX(G4–Q11) and its interaction with phosphatidylserine
Grant M. A., Baikeev R., Gilbert G. E., Rigby A. C.
Control of Factor Xa activity by heparin in plasma is related to the inhibition of free Factor Xa
Fiore M. M., Kakkar V. V.
Correlation of supra-therapeutic (ST) International Normalized Ratio (INR) with vitamin-K-dependent factors (VKDF)
Sarode R., Rawal A., Lee R., Uchal L., Frenkel E. P.
Effect of Mg(II) ion on the interaction of factor IX with phospholipid membrane
Shikamoto Y., Morita T., Fujimoto Z., Mizuno H.
Effect of the direct factor Xa inhibitor, DX-9065a, on thrombin generation in patients with stable coronary artery disease
Alexander J. H., Becker R. C., Hasselblad V., Dyke C. K., Robertson T. L., Harrington R. A., Bovill E. G.
Evidence supporting a functional role for the metal binding site observed within the protease domain of Factor IXa
Goodwin C. A., Kakkar V. V., Scully M. F.
Expression of recombinant human gla-domainless factor X (gdFX) in the baculovirus: assessing substrate recognition by the intrinsic tenase complex
Yuan Q. P., Annis D. S., Kirkpatrick H. M., Mosher D. F., Sheehan J. P.
Factor VII deficiency and stroke: case report
Villaça P. R., D'Amico E. A., Bassitt R. P., Oliveira V., Rocha T. R. F., Chamone D. A. F.
Factor X Cardiff and Factor X Newcastle: Two new FX mutations associated with low activity and antigen levels
Deam S., Uprichard J., Dasani H., Lewis S., Perkins S. J., Hanley J., Dolan G.
Fatal intra cerebral hemorrhage due to severe vitamin K deficiency disclosing cystic fibrosis
Trichet C., Essouri S., Fabre M., Girodon-Boulandet E., Devictor D., Jacquemin E., Dreyfus M.
FIX Gla Domain: Identification and characterization of residues involved in the phosphatidylethanolamine/phosphatidylserine phospholipid membrane interaction
Schenone M., Rigby A. C., Furie B., Furie B. C.
Functional pan-universality of the age-related regulatory elements ASE and AIE, and development of age dimension technology
Kurachi K., Fontaine J.-M., Abe T., Kurachi S.
Genetic profiling of 20 patients with FVII deficiency by dHPLC and sequence analysis: detection of 7 novel mutations
Geisen C., Freyaldenhoven B., Söhngen D., Schulz A., Daugela L., Watzka M., Pavlova A., Ivaskevicius V., Wielckens K., Seifried E., Oldenburg J.
Human vitamin K-dependent Gas6 gene: exon–intron structure and identification of allelic variants
Muñoz X., Amador-Arjona A., Sumoy L., Garcia de Frutos P., Sala N.
Identification of a binding site for glycoprotein Iba in the Apple 3 domain of factor XI
Baglia F. A., Lopez J. A., Walsh P. N.
Identification of a Factor IX cleaving protease and efficient reduction in a high purity Factor IX manufacturing process
Kundu S., Bigler D., Lind H., Schulte S.
Identification of transcription factor binding sites for HNF1-alpha, FOXA2, HNF4-alpha, Sp1 and Sp3 in the human prothrombin gene enhancer
Ceelie H., Spaargaren-Van Riel C. C., De Jong M., Bertina R. M., Vos H. L.
Impact of direct thrombin inhibitors on actions of vitamin K antagonists on analysis with different coagulation parameters: aPTT and PT for argatroban, hirudin and melagatran
Fenyvesi T., Trager I., Giese C., Jorg I., Harenberg J.
Inhibition of human prothrombinase by PD0313052 reveals advantages of active site-directed factor Xa inhibition
Gould W. R., Welch K. M., Bryant J. W., Leadley R. J.
Limited ability of nonactivated partial thromboplastin time to monitor clotting factors activation in high purity/high potency Factor IX concentrates
Grancha S., Massot M., Jorquera J. I.
Mechanisms of homeostasis of blood coagulation factors
Kurachi S., Zhang K., Kuwahara M., Kurachi K.
Molecular basis of the bleeding disorder caused by Prothrombin-Vancouver
Hewitt J., Duke L. M., Vo H. C., Nguyen V. H., Maxwell A. H., Johnstone S., Chan K-W, Wu J. K., Wadsworth L. D., Macgillivray R. T. A.
Molecular events involved in factor IXa stimulation by the factor VIII A2 domain
Fribourg C., Van Stempvoort G., Kolkman J. A., Meijer A. B., Mertens K.
Mutations in genes of the gamma-glutamyl carboxylase and the vitamin K epoxidase reductase complex are responsible for the phenotype of hereditary combined deficiency of vitamin K-dependent clotting factors
Oldenburg J., Rost S., Fregin A., Kavakli K., Koch D., Compes M., Eberl W., Wolz W., Schurgers L. J., Vermeer C., Seifried E., Mueller C. R.
Preparation of prothrombin complex concentrate (PCC) at intermediate scale: first experience in Argentina
Bernardi M. E., Bermudez M. C., Hurvitz A., Oviedo S. A., Moya C., Zingale G., Vitali M. S., Zarzur J. A.
Proteases derived from Ficus carica activate human factor X
Richter G., Schwarz H. P., Turecek P. L.
Role of basic residues of proexosite 1 on prothrombin in the prothrombinase complex
Yang L., Manithody C., Rezaie A. R.
Role of the Gla and first EGF-like domains of Factor X in the Prothrombinase and Tissue Factor-Factor VIIa complexes
Thiec F., Cherel G., Christophe O. D.
The omega-loop within the Gla domain (G4–Q11) and the EGF2 domain (C88–C124) of factor IXa are both essential for the assembly of the FX activating complex on activated platelets
Yang X., Walsh P. N.
The substitution of the factor Xa a-helix 345–352, which is a factor Va interactive site, by the corresponding structure of factor IXa does not affect formation and activity of the prothrombinase complex
Thiec F., Cherel G., Christophe O. D.
The thrombogenic agent in prothrombin complex concentrates (PCC): Identification of elevated levels of prothrombin as the major cause
Hanker-Dusel C., Eich S., Grundmann C., Seitz R., König H.
Use of constant infusion of recombinant factor VIIa (NovoSeven) in the management of a recurrent subdural hematoma in a patient with severe hepatic coagulopathy
Nolen J. D. L., Duncan A., Martinez E., Iyengar S.
Usefulness of the prothrombin level measured by the carinactivase-1 method as the parameter of the coagulation activity during chronic warfarin therapy
Iwade K., Aosaki M., Tatsumi F., Matsuo T., Sekino T., Katsume T., Morita T.